Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus as Adjunctive Treatment for Focal Refractory Epilepsy
NCT06719791Phase 1Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sirolimus in epilepsy, sponsored by Xuanwu Hospital. Primary endpoints: Percent Change From Baseline in Seizure Frequency Per 28 Days and 50% Seizure Responder Rate at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
sirolimus
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06719791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719791.